Financial reports
10-K
2023 FY
Annual report
29 Mar 24
20-F
2022 FY
Annual report (foreign)
28 Apr 23
20-F
2021 FY
Annual report (foreign)
16 May 22
NT 20-F
Notice of late annual filing (foreign)
29 Apr 22
20-F
2020 FY
Annual report (foreign)
21 Apr 21
20-F
2019 FY
Annual report (foreign)
30 Mar 20
20-F
2018 FY
Annual report (foreign)
23 Apr 19
20-F
2017 FY
Annual report (foreign)
18 Jul 18
NT 20-F
Notice of late annual filing (foreign)
1 May 18
20-F
2016 FY
Annual report (foreign)
31 Mar 17
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Apr 24
8-K
Akari Therapeutics Reports Full-Year
1 Apr 24
8-K
Entry into a Material Definitive Agreement
11 Mar 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
8-K
Akari Therapeutics Announces Existing Investors Support the Company
2 Jan 24
6-K
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
1 Dec 23
6-K
Current report (foreign)
16 Nov 23
6-K
Current report (foreign)
29 Sep 23
6-K
Akari Therapeutics Announces Existing Investors Support the Company
21 Sep 23
6-K
Current report (foreign)
5 Sep 23
Registration and prospectus
425
Business combination disclosure
11 Mar 24
425
Business combination disclosure
5 Mar 24
425
Business combination disclosure
5 Mar 24
D
$2.00 mm in equity / securities to be acquired, sold $2.00 mm, 2 investors
9 Jan 24
424B3
Prospectus supplement
27 Oct 23
POS AM
Prospectus update (post-effective amendment)
20 Oct 23
POS AM
Prospectus update (post-effective amendment)
20 Oct 23
F-3
Shelf registration (foreign)
20 Oct 23
D
$1.97 mm in equity / options / securities to be acquired, sold $1.97 mm, 11 investors
19 Oct 23
S-8
Registration of securities for employees
12 Oct 23
Proxies
DEFA14A
Additional proxy soliciting materials
18 May 16
DEF 14A
Definitive proxy
28 Apr 16
DEFA14A
Additional proxy soliciting materials
9 Sep 15
DEFA14A
Additional proxy soliciting materials
18 Aug 15
DEFA14A
Additional proxy soliciting materials
18 Aug 15
DEFA14A
Additional proxy soliciting materials
13 Aug 15
DEFM14A
Proxy related to merger
3 Aug 15
DEFA14A
Additional proxy soliciting materials
15 Jul 15
PREM14A
Preliminary proxy related to merger
15 Jul 15
DEFA14A
Additional proxy soliciting materials
13 Jul 15
Other
EFFECT
Notice of effectiveness
27 Oct 23
CORRESP
Correspondence with SEC
25 Oct 23
EFFECT
Notice of effectiveness
24 Oct 23
EFFECT
Notice of effectiveness
24 Oct 23
UPLOAD
Letter from SEC
24 Oct 23
EFFECT
Notice of effectiveness
7 Jun 23
EFFECT
Notice of effectiveness
7 Jun 23
EFFECT
Notice of effectiveness
9 Nov 22
CORRESP
Correspondence with SEC
7 Nov 22
UPLOAD
Letter from SEC
19 Oct 22
Ownership
SC 13D/A
RPC Pharma Ltd
4 Jan 24
3
Rachelle Suzanne Jacques
2 Jan 24
3
WENDY F DICICCO
2 Jan 24
3
Samir Rashmikant Patel
2 Jan 24
3
Mohamed Wa'el Ahmed Hashad
2 Jan 24
3
Raymond Prudo-Chlebosz
2 Jan 24
3
Michael Grissinger
2 Jan 24
3
DONALD A WILLIAMS
2 Jan 24
SC 13D/A
RPC Pharma Ltd
20 Oct 23
SC 13D/A
RPC Pharma Ltd
14 Apr 23